Compare Abbott Laboratories (ABT) vs CAVA Group Inc (CAVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs CAVA Group Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while CAVA Group Inc trades at $67.64 (market cap $8.12B). The key difference: Abbott Laboratories is far larger — about 20.6× CAVA Group Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| ABT | CAVA | |
|---|---|---|
Market Cap | $166.94B | $8.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $97.39 |
52-Week Low | $82.57 | $43.59 |
Enterprise Value | $193.69B | $8.22B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
CAVA stock is trading at $71.91, down 6.46% with a bearish technical signal. The company shows strong revenue growth reaching $1.18 billion in 2025 with positive net income of $63.74 million, though valuation metrics remain elevated with a P/E of 138.29. Recent earnings beat expectations in Q1 2026 with $0.20 EPS versus $0.17 expected. Analyst sentiment remains strongly positive with 72% buy ratings and a $94.19 consensus price target, representing 31% upside potential from current levels.
The outlook remains favorable given CAVA's expansion trajectory and market share gains in the fast-casual segment, though high valuation multiples and margin pressures present risks. The stock's recent pullback offers potential entry point for growth investors, but requires monitoring of same-store sales trends and competitive dynamics in the restaurant industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
